Related posts
Markets rise, but mixedThis summary was created by AI, based on 2 opinions in the last 12 months.
Biohaven Pharmaceutical (BHVN-N) has been experiencing ups and downs in the stock market. The FDA's refusal to review one of their drugs led to a sell-off, but some experts see this as a potential buying opportunity. The company is currently not profitable, but there is optimism surrounding their new drugs in the pipeline. Biohaven's recent R&D day resulted in a significant increase in share price, signaling investor faith in their future prospects.
The new Biohaven began trading last October after Pfizer bought the old one only for its migraine drug. The new Biohaven is far more speculative because there are many drugs in the pipeline in early stages. They held an R&D day this week and shares soared. He has faith in their new drugs.
Biohaven Pharmaceutical is a American stock, trading under the symbol BHVN-N on the New York Stock Exchange (BHVN). It is usually referred to as NYSE:BHVN or BHVN-N
In the last year, 2 stock analysts published opinions about BHVN-N. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Biohaven Pharmaceutical .
Biohaven Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Biohaven Pharmaceutical .
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Biohaven Pharmaceutical In the last year. It is a trending stock that is worth watching.
On 2024-04-25, Biohaven Pharmaceutical (BHVN-N) stock closed at a price of $38.54.
Shares sold off last week after the FDA refused to review one of their drugs. Could be a buying opportunity, but the company is losing money.